The RANK/RANKL pathway is often overexpressed and has been positively correlated with tumor progression and advanced disease in primary malignant tumors of the bone, including osteosarcoma, multiple myeloma, and GCTB [16,17,18,19,20]. Here, TNFRSF11A is linked to plasma cell myeloma.